Caladrius Biosciences (NASDAQ:CLBS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Caladrius Biosciences (NASDAQ:CLBSGet Rating) in a research report issued on Tuesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

A number of other research firms have also recently commented on CLBS. HC Wainwright decreased their target price on shares of Caladrius Biosciences from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, March 23rd. Zacks Investment Research upgraded shares of Caladrius Biosciences from a “hold” rating to a “buy” rating and set a $0.50 price objective on the stock in a research report on Tuesday, May 24th.

NASDAQ CLBS opened at $0.51 on Tuesday. Caladrius Biosciences has a 12 month low of $0.40 and a 12 month high of $1.68. The stock has a market cap of $31.11 million, a price-to-earnings ratio of -1.28 and a beta of 1.10. The company’s 50 day moving average is $0.57 and its two-hundred day moving average is $0.72.

Caladrius Biosciences (NASDAQ:CLBSGet Rating) last released its earnings results on Thursday, May 5th. The biotechnology company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03. During the same quarter in the prior year, the firm posted ($0.19) EPS. Sell-side analysts predict that Caladrius Biosciences will post -0.4 earnings per share for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in CLBS. Barclays PLC raised its position in shares of Caladrius Biosciences by 239.4% during the third quarter. Barclays PLC now owns 21,103 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 14,885 shares during the last quarter. Two Sigma Securities LLC bought a new stake in shares of Caladrius Biosciences during the third quarter valued at approximately $33,000. Alterna Wealth Management Inc. bought a new stake in shares of Caladrius Biosciences during the fourth quarter valued at approximately $61,000. Goldman Sachs Group Inc. bought a new stake in shares of Caladrius Biosciences during the second quarter valued at approximately $87,000. Finally, Millennium Management LLC raised its position in shares of Caladrius Biosciences by 46.2% during the second quarter. Millennium Management LLC now owns 64,903 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 20,498 shares during the last quarter. Hedge funds and other institutional investors own 18.76% of the company’s stock.

About Caladrius Biosciences (Get Rating)

Caladrius Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease.

Recommended Stories

Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.